On May 20, 2025, International Clinical Trials Day, Ethiopia took a significant step in strengthening its public health research infrastructure. Under the leadership of the Armauer Hansen Research Institute (AHRI) and in collaboration with the Ministry of Health and other local partners, the country officially launched the Clinical Trials Network in Ethiopia (CTN-ET). Over two days of hybrid sessions in Addis Ababa, more than 200 stakeholders gathered to mark this milestone.
The establishment of CTN-ET responds directly to Council of Ministers Regulation No. 530/2023, which charges AHRI with leading and building capacity for clinical trials and bioequivalence activities nationwide.
Why It Matters
One highlight was Ethiopia’s recent attainment of Regulatory Maturity Level 3 in clinical trial oversight. Ms. Heran, Director General of EFDA, emphasized that this status reflects the country’s ability to host high-quality, multi-center trials and expedite ethical and regulatory reviews. She noted EFDA’s investments in digital systems and staff training, which “are now bearing fruit” in more efficient approval processes. EFDA reaffirmed its full support for CTN-ET, pledging to strengthen collaboration with AHRI and other stakeholders.
International partners also shared insights on CTN-ET’s potential impact. Dr. Patrick Avoc, WHO Ethiopia’s Health Emergencies Preparedness and Response Lead, stressed that clinical trials must be inclusive and locally relevant. “Without diverse data, we risk solutions that fail significant population segments,” he warned. Dr. Mosoka Papa Fallah of Africa CDC highlighted how trial capacity underpins pandemic preparedness. “Clinical trials are essential tools for outbreak prevention and response. Networks like CTN-ET ensure Africa’s readiness before the next crisis.”
Speakers pointed to AHRI’s performance during the COVID-19 pandemic as proof of Ethiopian researchers’ capabilities. Under AHRI’s guidance, local teams quickly implemented treatment and vaccine trials, maintaining rigorous scientific and ethical standards. These experiences laid the groundwork for CTN-ET, which will now harness that momentum to support a broader range of health priorities—tuberculosis, malaria, noncommunicable diseases, and beyond.
CTN-ET’s Mission and First Steps
Dr. Mekonnen Teferi, Director of AHRI’s Clinical Trials Directorate, outlined CTN-ET’s initial focus areas:
- Partnership Building: Forge links among clinical trial sites (both urban and rural), academic institutions, CROs, ethics committees, pharmaceutical companies, and NGOs.
- Capacity Strengthening: Roll out standardized training in Good Clinical Practice, research ethics, and data management.
- Digital Infrastructure: Implement an online platform to manage trial protocols, ethical approvals, and site performance in real time.
- Community Engagement: Involve civil society groups to ensure trial designs reflect community needs and uphold participant welfare.
These steps aim to position Ethiopia as a premier hub for high-impact clinical research in Africa, driving equitable health solutions continentwide.
What Lies Ahead
By the end of the launch, participants agreed on key priorities: securing sustainable funding, maintaining regulatory agility, fostering local leadership, and building community trust. AHRI teams are already coordinating working groups to finalize standard operating procedures, identify site gaps in underrepresented regions, and plan upcoming capacity-building workshops.
Looking for more scholarships, fellowships, internships, and professional development programmes?
Follow us on Telegram at @medinethiopiainsider
Subscribe to our website : medinethiopia.com
We publish verified opportunities every week tailored for health professionals across Ethiopia.
